Q32 Bio Inc.
Close on Oct 19, 2026
- Market cap
- $158.47M
- P/E (TTM)
- 3.2
- Dividend yield
- –
About Q32 Bio
Pharmaceutical Preparations, SIC 2834
Q32 Bio Inc. is a clinical-stage biotechnology company that develops biological therapies to restore immune balance in patients affected by autoimmune and inflammatory diseases. Its primary product candidate is bempikibart, a fully human monoclonal antibody antagonist that blocks signaling driven by interleukin-7 and thymic stromal lymphopoietin. The company develops bempikibart for autoimmune disorders, focusing specifically on individuals with alopecia areata. It has also created a proprietary tissue-targeted complement inhibitor platform that includes pre-clinical therapies such as ADX-096. Because its product candidates remain in development, the company has not commercialized products or established a commercial customer base.
The company operates in the United States and maintains its corporate headquarters and principal executive offices in Waltham, Massachusetts. As a clinical-stage enterprise, it has no commercial storefronts or physical distribution footprint. Its clinical trial evaluations include studies involving clinical trial participants, with more than 150 individuals dosed with bempikibart across completed and ongoing clinical trials.
Summary of the business section of Q32 Bio's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Q32 Bio Inc.
- Headquarters
- Waltham, MA
- Address
- 830 Winter Street 02451
- Phone
- (781) 999-0232
- Website
- q32bio.com
- Employees
- 24, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Ernst & Young LLP, Boston, Massachusetts, USA
Stock & identifiers
- Ticker
- QTTB
- Exchange
- Nasdaq
- IPO date
- Mar 29, 2018
- Shares outstanding
- 30M, Aug 3, 2026
- Public float
- $10.40M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-166 reverse, May 9, 2024; 1-for-18 reverse, Mar 26, 2024
- SEC CIK
- 1661998
- CUSIP
- 746964105
- ISIN
- US7469641051
- LEI
- 549300RWKPJEFTM3K452
- EIN
- 47-3468154
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Jodie Pope Morrison | CEO, Director | 343,259 |
| Lee Kalowski | CFO and President | 138,471 |
| Shelia M. Violette | Chief Scientific Officer | 164,048 |
| Jason Campagna | Chief Medical Officer | 37,500 |
| Mary Thistle | Director | – |
| David S. Grayzel | Director | 2,092,106 |
| Kathleen Laporte | Director | 5,431 |
| Diyong Xu | Director | 625,000 |
| Mark T. Iwicki | Director | – |
| Arthur Tzianabos | Director | 7,983 |
| Sven Ante Lundberg | Director | 1,200 |
| Isaac Manke | Director | 53,521 |
| Genesis GP LLC OrbiMed | Director | – |
| Capital GP VII LLC OrbiMed | Director | 3,502,987 |
| Advisors Llc Orbimed | Director | 2,252,987 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Albert Seymour Ph D | $0 | $0 | $880.80K | $15 | – |
| FY2025 Jodie Morrison | $1.56M | $1.21M | $880.80K | $15 | – |
| FY2025 Paul Alloway Ph DJD | $0 | $0 | $880.80K | $15 | – |
| FY2024 Albert Seymour Ph D | $0 | $0 | $2.20M | $1517 | – |
| FY2024 Jodie Morrison | $6.00M | $2.09M | $2.20M | $1517 | – |
| FY2024 Paul Alloway Ph DJD | $758.14K | $708.39K | $2.20M | $1517 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 24 full-time employees, of which 3 have M.D.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Dec 1, 2025 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| May 23, 2025 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Mar 27, 2024 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Mar 27, 2024 | Auditor change | Change in certifying accountant (8-K Item 4.01) |
| Mar 22, 2024 | Name change | Name changed from Homology Medicines, Inc. to Q32 Bio Inc. |
| Jan 3, 2024 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Dec 18, 2023 | Merger | Registration of securities for a merger or exchange offer (S-4) |
| Mar 16, 2022 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Mar 29, 2018 | IPO | Initial public offering priced (424B4 prospectus) |
| Mar 19, 2018 | Listing | Registration of securities on an exchange (Form 8-A) |